Shares of Oncobiologics Inc (NASDAQ:ONS) have been given an average broker rating score of 3.00 (Hold) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating. Oncobiologics’ rating score has declined by 200% from three months ago as a result of a number of analysts’ upgrades and downgrades.
Analysts have set a one year consensus target price of $11.00 for the company, according to Zacks. Zacks has also given Oncobiologics an industry rank of 196 out of 265 based on the ratings given to its competitors.
A number of brokerages have commented on ONS. ValuEngine raised shares of Oncobiologics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Barclays downgraded shares of Oncobiologics from an “overweight” rating to an “equal weight” rating in a research note on Monday, January 29th.
An institutional investor recently raised its position in Oncobiologics stock. Sabby Management LLC increased its holdings in shares of Oncobiologics Inc (NASDAQ:ONS) by 5.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,365,763 shares of the company’s stock after buying an additional 127,293 shares during the period. Sabby Management LLC owned about 9.59% of Oncobiologics worth $2,371,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 17.90% of the company’s stock.
Shares of Oncobiologics (ONS) traded down $0.07 during mid-day trading on Wednesday, reaching $1.17. 8,621 shares of the company’s stock were exchanged, compared to its average volume of 63,922. The company has a quick ratio of 0.14, a current ratio of 0.14 and a debt-to-equity ratio of -0.40. Oncobiologics has a one year low of $0.78 and a one year high of $3.77. The stock has a market capitalization of $29.17 and a P/E ratio of -0.69.
TRADEMARK VIOLATION WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/02/07/analysts-set-11-00-price-target-for-oncobiologics-inc-ons.html.
Oncobiologics Company Profile
Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.